ARPA‑H awarded BioCurie up to $9.3 million to develop an AI‑powered digital platform aimed at accelerating and de‑risking gene therapy manufacturing. The grant funds computational modeling, machine‑learning driven process optimization, and integration of real‑world manufacturing data to replace iterative trial‑and‑error process development, the agency and company said. BioCurie will partner with academic and industry groups including St. Jude Children’s Research Hospital and the Center for Breakthrough Medicines. CEO Irene Rombel described the work as an effort to reduce timelines and costs for viral and non‑viral genomic medicines, with the goal of making advanced therapies more scalable and affordable.